Small Molecules in Oncology

Overview of attention for book

Cover of 'Small Molecules in Oncology'

Table of Contents

Attention for Chapter 13: Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET

Altmetric Badge

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 51 Mendeley

Summary Dimensions citations

You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Chapter title	Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET
Chapter number	13
Book title	Small Molecules in Oncology
Published in	Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
DOI	10.1007/978-3-319-91442-8_13
Pubmed ID	30069768
Book ISBNs	978-3-31-991441-1, 978-3-31-991442-8
Authors	Stefanie Zschäbitz, Carsten Grüllich, Zschäbitz, Stefanie, Grüllich, Carsten
Abstract	Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRα), and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer and in combination with everolimus for the treatment of advanced renal cell carcinoma following anti-VEGF treatment. In hepatocellular carcinoma lenvatinib was non inferior to sorafenib in first line with an improved progression-free survival and approval in this indication is expected. Lenvatinib is currently investigated for further indications as single agent and in combinations. Side effects include typical TKI induced toxicities such as hypertension, diarrhea, hypothyroidism, and fatigue.

View on publisher site Alert me about new mentions

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Unknown	51	100%

Demographic breakdown

Readers by professional status	Count	As %
Student > Doctoral Student	6	12%
Student > Master	5	10%
Student > Bachelor	5	10%
Student > Ph. D. Student	5	10%
Student > Postgraduate	4	8%
Other	8	16%
Unknown	18	35%

Readers by discipline	Count	As %
Pharmacology, Toxicology and Pharmaceutical Science	7	14%
Medicine and Dentistry	5	10%
Biochemistry, Genetics and Molecular Biology	5	10%
Chemistry	4	8%
Unspecified	3	6%
Other	7	14%
Unknown	20	39%